TY  - JOUR 
AU  - Jiménez-Solas, Tamara
AU  - López-Cadenas, Félix
AU  - Aires-Mejía, Irene
AU  - Caballero-Berrocal, Juan Carlos
AU  - Ortega, Rebeca
AU  - Redondo, Alba María
AU  - Sánchez Guijo Martín, Fermín
AU  - Muntión Olave, María Sandra
AU  - García-Martín, Luís
AU  - Albarrán, Beatriz
AU  - Alonso, José María
AU  - Del Cañizo, Consuelo
AU  - Hernández Hernández, Ángel
AU  - Díez-Campelo, María
PY  - 2019
SN  - 0007-1048
UR  - http://hdl.handle.net/10366/155179
AB  - [EN]Patients with low-risk myelodysplastic syndromes (MDS) usually develop iron overload. This leads to a high level of oxidative stress in the bone marrow (BM) and increases haematopoietic cell dysfunction. Our objective was to analyse whether...
LA  - eng
PB  - Wiley
KW  - Myelodysplastic syndromes
KW  - Deferasirox
KW  - Iron overload
KW  - Reactive oxygen species
KW  - DNA damage
KW  - Bone Marrow Cells
KW  - Oxidative Stress
KW  - Case-Control Studies
KW  - Reactive Oxygen Species
KW  - Cell Differentiation
KW  - Humans
KW  - Iron Overload
KW  - DNA Damage
KW  - Iron Chelating Agents
KW  - Prospective Studies
KW  - Oxidation-Reduction
KW  - Myelodysplastic Syndromes
KW  - Stem Cells
TI  - Deferasirox reduces oxidative DNA damage in bone marrow cells from myelodysplastic patients and improves their differentiation capacity
DO  - 10.1111/bjh.16013
T2  - British Journal of Haematology
VL  - 187
M2  - 93
ER  -